Re: HCLS chartering/next steps Thur 26 May

I agree with Tim's ideas. The different task forces should be problem-focused. This would also help to reduce the redundancy between task forces (for example, the original idea of BioRDF was mainly to convert biomedical data to RDF, but over the years this also became a major focus of other task forces such as LODD).

 - Matthias


From: Tim Clark 
Sent: Thursday, May 26, 2011 3:55 PM
To: HCLS IG 
Cc: Mikel Egaña Aranguren ; Helena Deus 
Subject: Re: HCLS chartering/next steps Thur 26 May


Dear HCLS colleagues 


I guess my comment would be, setting Translational Medicine as a major priority = ok, making it the only priority = not ok.   


TM applications are important, and do potentially integrate many of the things we have all been working on. But they are far from covering all the bases, and far from covering all the use cases of critical concern to people in my Task Group, Scientific Discourse. 


I'll just observe that since we launched the multiple task groups we have ended up with two kinds of groups:  


(1) Problem Centric, e.g. TM and Scientific Discourse 
(2) Solution Centric, e.g. LODD, BioRDF, Terminology


My personal recommendation would be to formulate the charter around accelerating biomedical research and promoting cross-discipline sharing, across the full scientific and clinical life cycle.  I would begin by dividing into several distinct problem focused areas. I would lose the solution-based Task Groups and reformulate them as problem-based.


for example, BioRDF has been working on gene lists for transcriptomic experiments, we might recharter that Task Group to work on Genomic Experiments, for example, or whatever concept area the Task members like and is a logical step from what they are doing now, but with a PROBLEM FOCUS ... you see the point. 


I think each of the solution centric groups has a potential problem centric group hiding inside it, waiting to come out.


Best


Tim


On May 26, 2011, at 9:31 AM, Helena Deus wrote:


  Hi, 

  That is a very good point, thanks Mikel and Andrea!
  Do you have pointers to such type of data? Shall we consider an IG for "basic" life sciences?


  The LS part of HCLS has indeed been gaining adepts rapidly and it may make sense to reflect that in the charter. 


  Cheers,
  Lena


  2011/5/26 Mikel Egaña Aranguren <megana@fi.upm.es>

    Hi;

    I should attend the conference call but I just want to add that I concur with Andrea in that the HCLS IG should consider the environmental realm, since loads of new ecological/environment data, with new challenges to be addressed, are waiting to be represented semantically. That's precisely one of the lines we are trying to open here at OEG-UPM.

    Cheers 


    On og., 2011.eko mairen 26a 15:08, Andrea Splendiani wrote:

      Hi,

      I see myself as more involved in the next incarnation of the charter ;)
      Unfortunately, today is a travel day and I cannot attend the conference
      call.

      I have two questions/ideas, which don't really map to the current
      sub-groups, but just in case they ring some bell:

      -) Is the HCLS exclusively oriented on HeathCare ? (that is, is the "and" in
      Heath Care and Life Sciences IG and AND or an OR ?). Here in Rothamsted, we
      are just starting to evaluate the Ecological/Agricultural/Environmental
      connections to Life Sciences. Does this fall into the remit of the IG group
      ?

      -) Does the evaluation/ coordination of development of systems which link
      information representation and analysis side fall within the remit of the IG
      ? I think interfaces to linked data, as well as tools which can analyze
      linked data are important to improve the acceptance of Semantic Web
      technologies in the Life Sciences.

      ciao,
      Andrea




      Il giorno 24/mag/2011, alle ore 04.04, Eric Prud'hommeaux ha scritto:


        Hi all, as some of you reallize, the charter ends at the end of this
        month. I've been polling around to see what alternative formulations
        would give us the most resources and impact. In the process, I wrote
        up some of our high-level use cases (elevator speeches) to help us
        approach the relevant parties in pharmas, health services and
        research:<http://www.w3.org/2011/05/HCLSIGUseCases>.

        I'd like to discuss the landscape and potential strategies with the
        community. I'd particularly like to invite those who have been active
        or see themselves as being active in the next incarnation of the group.
        We'll discuss the current, fairly conservative draft charter
        <http://www.w3.org/2011/05/HCLSIGCharter-proposal>, as well as ways to
        optimize both its message and the paths for dissemination. An example
        of a messaging alternative would be to characterize the HCLS IG work
        in terms of e.g. overarching translational medicine use cases:
        "
         The W3C Semantic Web in Health Care and Life Sciences Interest Group
         focuses on translational medicine use cases. The group will continue
         the aggregation of cutting edge and traditional scientific knowledge
         to meet use cases for researchers, care givers, patients and
         regulatory agencies. Due to the scope and diversity of expertise
         required to meet translational needs, the HCLS IG work is broken
         down into discrete task forces focused on particular data
         acquisition, modeling and integration requirements:

         Terminology - identifying and integrating identifiers for biological
         processes, gross anatomy and medical procedures to promote
         unification of domain data.

         LODD - curation of compounds, clinical trials and outcomes.

         BioRDF - modeling of biological processes and actors.

         Scientific Discourse - representation and tracking of the changing
         landscape of scientific knowledge and the driving theora and
         experiments.

         Translational Medicine - the oversight and high-level ontology that
         connects these disciplines together in order to meet immediate and
         long term needs from pharma, health care and other vested parties.
        "
        . Perhaps you all have some other ideas about how to tell a story
        about our work which will serve to both draw people to our work and
        our products and to help already interested parties find the task
        forces which interest them. I of course want to draw an optimal
        balance between doing work which motivates the participants and
        focusing on tasks which will accelerate education and adoption by
        important organizations.

        I'm sure you are all aware of my preference for technical work, but I
        feel that this outreach can make us all ultimately more effective. I
        will use the Thursday 26 May HCLS slot (11:00 EDT) to reach out to the
        current HCLS IG community, and whomever else you folks elect to bring
        along. Of course, I'll reserve extra teleconference slots, but please
        RSVP to me privately so I can make a guess at how many ports to
        reserve. Also, please provide what feedback you can before the
        conference. Anything we take care of before will make the meeting more
        efficient.

        Conference Details

        Date of Call: Thursday, May 26, 2011
        Time of Call: 11:00 am Eastern Time, 4 pm UK, 5 pm CET
        Dial-In #: +1.617.761.6200 (Cambridge, MA)
        [Note: limited access to European dial in numbers below]
        Dial-In #: +33.4.26.46.79.03 (Nice, France)
        Dial-In #: +44.203.318.0479 (Bristol, UK)
        Participant Access Code: 4257 ("HCLS")
        IRC Channel: irc.w3.org port 6665 channel #HCLS (see W3C IRC page for
        details, or see Web IRC), Quick Start: Use
        http://www.mibbit.com/chat/?server=irc.w3.org:6665&channel=%23hcls for
        IRC access.
        Duration: ~1 hour
        Convener: Eric Prud'hommeaux
        Scribe: TBD

        HCLS IG charter/strategy discussion
        -- 
        -ericP


      Andrea Splendiani
      Senior Bioinformatics Scientist
      Centre for Mathematical and Computational Biology
      +44(0)1582 763133 ext 2004
      andrea.splendiani@bbsrc.ac.uk









    -- 
    Mikel Egaña Aranguren, PhD
    http://mikeleganaaranguren.com

    Marie Curie post-doc at Ontology Engineering Group, UPM
    http://www.oeg-upm.net/






  -- 
  Helena F. Deus 
  Post-Doctoral Researcher at DERI/NUIG
  http://lenadeus.info/






The information in this e-mail is intended only for the person to whom it is
addressed. If you believe this e-mail was sent to you in error and the e-mail
contains patient information, please contact the Partners Compliance HelpLine at
http://www.partners.org/complianceline . If the e-mail was sent to you in error
but does not contain patient information, please contact the sender and properly
dispose of the e-mail.